Dupixent “addresses current gap” in COPD biologics landscape [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
The European Medicines Agency (EMA) greenlit the anti-inflammatory blockbuster drug earlier this week, marking the first advancement in the COPD space in more than a decade. GlobalData healthcare analyst Asiyah Nawab said: “The EMA's approval of Dupixent has addressed a current gap in the market for COPD - the absence of biologics.” Dupixent, which targets interleukin-4 (IL4) and interleukin-13 (IL13), was approved by the EMA as an add-on maintenance treatment alongside current therapies. These include inhaled corticosteroids and bronchodilators, which control inflammation and relax and widen airways in the lungs. Nawab said that key opinion leaders (KOLs) interviewed by GlobalData have shared optimistic views on Dupixent, noting that its novel pathway presents anti-mucous effects – a bonus on top of its anti-eosinophil effects. Nawab said: “The approval is set to improve the treatment landscape for COPD and offer patients a treatment option with the potential to improve qual
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- How effective is the flu shot this year? New report reveals 'disappointing' data [USA TODAY]USA TODAY
- US to double emergency bird flu vaccines as more people, herds become infected [USA TODAY]USA TODAY
- Sanofi consumer health unit bidders revising offers over talc powder concerns - report [Seeking Alpha]Seeking Alpha
- Sanofi Healthcare Bidders Revising Offers Over Talc Concerns [BNN Bloomberg (Canada)]BNN Bloomberg
- Sanofi Healthcare Bidders Revising Offers Over Talc Concerns [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 10/2/24 - Form 6-K
- 9/24/24 - Form 6-K
- 9/13/24 - Form 6-K
- SNY's page on the SEC website